| | Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011. | 19/01/23 17:50 | Insider Trading / SAST |  |
| | The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on January 19, 2023 for Dharmavati Bhutada & Others | |
| |
| | Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011. | 19/01/23 17:49 | Insider Trading / SAST | |
| | The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on January 18, 2023 for Dharmavati Bhutada & Others | |
| |
| | Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011 | 19/01/23 15:22 | Insider Trading / SAST | |
| | The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on January 19, 2023 for Dharmavati Bhutada & Others | |
| |
| | Disclosure Under Regulation 7(2) Of SEBI (Prohibition Of Insider Trading) Regulations, 2015. | 18/01/23 20:09 | Company Update | |
| | Submission of Disclosure under Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015. | |
| |
| | Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015 | 28/10/22 18:22 | Company Update | |
| | With reference to our intimation dated 22 October 2022 with regard to the reporting of violation of Code of conduct for prohibition of Insider trading, We would like to inform Mr. Suraj innani has paid the penalty amount Rs. 25000/- to the Company and the Company has deposited the said amount to SEBI (Investor Protection and Education Fund) on 26 October 2022 vide UTR no 10516FZ01XVN. | |
| |
| | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 | 27/10/22 14:30 | Insider Trading / SAST | |
| | The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Pivotal Enterprises Pvt Ltd & PACs | |
| |
| | Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015 | 22/10/22 17:59 | Company Update | |
| | We would like to inform that one of the Designated Person of Shilpa Medicare Limited ('Company'), have traded in the equity shares of the Company in violation of the Code read with SEBI (Prohibition of Insider Trading) Regulations, 2015 ('PIT Regulations'). | |
| |
| | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 | 15/10/22 12:53 | Company Update | |
| | Pursuant to Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, Please find enclosed a Certificate dated 03 October 2022 for the quarter and half Year ended 30 September, 2022,
certifying that the details of securities dematerialized / rematerialized during the aforesaid period were maintained by "M/s. Kfin Technologies Limited" (SEBI Registration No. INR000000221), the Registrar and Share Transfer Agent of ShiIpa Medicare Limited. | |
| |
| | Announcement under Regulation 30 (LODR)-Newspaper Publication | 06/10/22 18:15 | Company Update | |
| | In continuation of our letter dated 28th September 2022 regarding outcome of the 35th Annual General Meeting, please find enclosed newspaper publication of e-voting results of the 35th Annual General Meeting held on 28th September 2022 in 'businessline' - all edition (English) on 04th October 2022. | |
| |
| | Shareholder Meeting / Postal Ballot-Scrutinizer''s Report | 30/09/22 15:43 | AGM/EGM | |
| | We wish to inform you that the 35th Annual General Meeting (AGM) of the Company and the business mentioned in the Notice convening the AGM were transacted.
In this regard, please find enclosed the following;
1. Submission of voting results in compliance with the provisions of regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2. Submission of Report of Scrutinizer dated 28th September, 2022 in compliance .... | |
| |
| | Closure of Trading Window | 30/09/22 15:37 | Insider Trading / SAST | |
| | we would like to inform you that pursuant to Code of Conduct for Regulating, Monitoring and Reporting Trading by Designated Persons and their Immediate Relatives, the Trading Window for dealing in the securities of the Company shall remain closed for all designated persons and their immediate relatives as covered under the said Code with effect from 01st October, 2022 till 48 hours after the declaration of Un-audited Financial Results of the Company .... | |
| |
| | Shilpa Medicare Limited, Analytical Services Division, Nacharam, Hyderabad, Telangana Has Received US FDA Clearance (EIR) For The Facility | 22/09/22 16:36 | Company Update | |
| | This is to inform you that the Company's Analytical Services Division situated at Nacharam, Hyderabad, Telangana has received US FDA clearance (EIR) for the inspection performed during 26 Apr 2022 to 29 Apr 2022.
This is the first US FDA inspection of this facility. The facility is identified as testing laboratory in numerous ANDAs filed by Shilpa Medicare Limited (Parent Organization) and its agreed parties. The FDA clearance on the facility will .... | |
| |
| | Shilpa'S Tranexamic Acid Spray (Hemostatic Spray) Is Approved By CDSCO (Dcgi) | 19/09/22 21:00 | Company Update | |
| | Shilpa would like to announce its successful innovation of first in world topical hemostatic spray of Tranexamic Acid has received CDSCO approval. This novel formulation of spray is simple, easy to carry, convenient to use and a lifesaving tool. Clinically proven in humans and validated in robust swine trauma model. The product is approved for the usage of reducing or preventing hemorrhage and to reduce the need of replacement therapy during accidental and domestic injury..... | |
| |
| | Intimation U/R 30 Of The SEBI (LODR) Regulations 2015- Reg. | 16/09/22 13:10 | Company Update | |
| | This is to inform you that the Company has received U.S Food and Drug Administration tentative approval for its ANDA, Tenofovir Alafenamide Tablets, 25 mg on 15 Sep 2022. The ANDA was filed as 'First to File' submission on NCE -1 date.
Tenofovir Alafenamide Tablets, 25 mg is a generic equivalent of reference listed drug (RLD) Vemlidy® tablets, of Gilead Sciences Inc. used in the treatment of chronic hepatitis B virus infection as recommended in .... | |
| |
| | Announcement under Regulation 30 (LODR)-Newspaper Publication | 08/09/22 16:50 | Company Update | |
| | Further to our letter dated 05th September 2022 regarding dispatch of Notice of 35th Annual General Meeting to be held on 28th September 2022 at 11.30 a.m. IST at the Registered Office of the Company through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM") to the shareholders of the Company, please find enclosed newspaper advertisements, published in compliance with Regulation 47(1)(d) of SEBI (Listing Obligations and Disclosure Requirements) .... | |
| |
| | Reg. 34 (1) Annual Report. | 05/09/22 22:14 | | |
| | Please find enclosed Notice convening the 35th Annual General Meeting (AGM) of the Company and Annual Report for the financial year 2021-2022 scheduled to be held on Wednesday, the 28th day of September 2022 at 11.30 A.M. IST at the Registered office of the Company through Video Conferencing ('VC') / Other Audio-Visual Means ('OAVM'), in accordance with the relevant circulars issued by the Ministry of Corporate Affairs and the Securities Exchange Board of India. | |
| |
| | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | 30/08/22 15:49 | Company Update | |
| | In furtherance to our intimation dated 23 August 2022 & 25 August 2022 with regard to the Q1 FY23 Conference Call held on Wednesday, August 24, 2022 at 03:45 PM IST, please find the enclosed transcript of the call. | |
| |
| | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | 25/08/22 11:07 | Company Update | |
| | Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and further to our letter dated August 23, 2022, please note that the audio recording of the conference call for Investors/Analysts for the discussion on Q1 FY23 results, held on August 24, 2022, at 3.45 PM (IST), has been uploaded on our website on the following web link:
https://www.vbshilpa.com/investor-presentation.php
| |
| |
| | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | 23/08/22 17:08 | Company Update | |
| | Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the schedule of Q1 FY23 Conference Call to be held on Wednesday, August 24, 2022 at 03:45 PM IST. | |
| |
| | Shilpa Medicare Limited Completes Human Clinical Studies Of
High Concentration Biosimilar Adalimumab
| 19/08/22 15:50 | Company Update | |
| | This is to inform you that the Company, via its wholly owned subsidiary, Shilpa Biologicals Pvt Ltd (SBPL), has successfully completed the phase 3 Human Clinical studies of its first biosimilar, the 100mg/ml High Concentration (HC) Adalimumab biosimilar and has submitted the dossier to the CDSCO for review and grant of marketing/manufacturing license - a first in India. | |
| |
| | Announcement under Regulation 30 (LODR)-Change in Directorate | 12/08/22 16:59 | Company Update | |
| | Appointment of Dr. Anita Bandyopadhyay (DIN No: 08672071), as an Additional Women Independent Director of the Company to hold office upto the date of ensuing Annual General Meeting and recommending her appointment as a Women Independent Director for a period of 3 years subject to members approval in the ensuing Annual General Meeting. | |
| |
| | Annual General Meeting' Of The Members Of The Company | 12/08/22 16:50 | AGM/EGM | |
| | This is to inform that the 35' Annual General Meeting (AGM) of the Members of the Company will be held on Wednesday, the 28" September 2022 at 11.30. a.m. IST through Video Conferencing (VC) / Other Audio-Visual Means (OAVM) in accordance with the relevant circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India. | |
| |
| | Announcement under Regulation 30 (LODR)-Investor Presentation | 12/08/22 16:23 | Company Update | |
| | With reference to the captioned subject, the Investor Presentation of the Company for the Quarter ended 30 June 2022 with regard to Business highlights, financial performance and other updates is attached herewith for your consideration.
| |
| |
| | Board Meeting Outcome- Financial Results | 11/08/22 18:46 | Result | |
| | This is to intimate that the Board of Directors in its meeting
held on 11th August 2022 which commenced at 02.30 p.m. and concluded at 6: 30 p.m. have inter alia considered and approved Un-Audited Financial Results (Standalone and Consolidated) for the quarter ended 30 June 2022. | |
| |
| | Compliance Requirement Of The Company And Certify That The Company Has Maintained A Structured Digital Database (SDD) Pursuant To Provisions Of Regulation 3(5) And 3(6) Of Securities And Exchange Board Of India (Prohibition Of Insider Trading) Regulations, 2015 | 09/08/22 18:36 | Company Update | |
| | Compliance requirement of the Company and certify that the Company has maintained a Structured Digital Database (SDD) pursuant to provisions of Regulation 3(5) and 3(6) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 | |
| |
| | Board Meeting Intimation for To Inter-Alia Consider The Un-Audited Standalone And Consolidated Financial Results For The Quarter Ended 30Th June 2022 | 03/08/22 16:41 | Board Meeting | |
| | SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2022 ,inter alia, to consider and approve Un-Audited Standalone and Consolidated Financial Results for the quarter ended 30th June 2022 | |
| |
| | Shilpa Medicare Limited, Unit III, Advanced Analytical Characterization Laboratory Clears US FDA Remote Record Review
| 29/07/22 15:56 | Company Update | |
| | This is to inform you that US FDA has concluded Remote Record Review of Shilpa Medicare Limited ('SML' or 'the Company'), Unit III, Advanced Analytical Characterization Laboratory situated at Dabaspet, Bengaluru, Karnataka without any objectionable conditions or observations. The review was conducted during 15th to 18th Nov 2021.
The facility is designed with advanced analytical equipment to provide testing services such as In-vitro Permeation .... | |
| |
| | Shilpa Medicare Limited Has Received Russian GMP For Unit I, Raichur API Facility. | 16/07/22 13:39 | Company Update | |
| | This is to inform that the Company's API facility (unit-1) located at Raichur, Karnataka has received GMP certificate from MOH-Russia. The facility was audited by the agency on 17 February 2022, 18 February 2022 and 21 February 2022.
The facility involves in manufacturing, testing, packing, storage of chemically synthesized non-sterile drug substances for human use.
| |
| |
| | Intimation U/R 30 Of The SEBI(Listing Obligations & Disclosure Requirements) Regulations, 2015 | 12/07/22 16:35 | Company Update | |
| | Shilpa Medicare Limited, Unit VI, Bengaluru facility has been issued UK MHRA GMP | |
| |
| | Intimation U/R 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 | 12/07/22 16:16 | Company Update | |
| | Shilpa Medicare Limited, Unit VI, Bengaluru facility has been issued UK MHRA GMP | |
| |
| | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 | 11/07/22 15:17 | Company Update | |
| | Please find attached copies of certificates sent to Central Depository Services (India) Limited and National Securities Depository Limited under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30.06.2022. | |
| |
| | Statement Of Investor Complaints For The Quarter Ended June 2022 | 11/07/22 15:12 | Company Update | |
| | | No.of Investor complaints pending at the beginning of the quarter | No.of Investor complaints received during the quarter | No.of Investor complaints disposed of during the quarter | No.of Investor complaints unresolved at the end of the quarter |
|---|
| 0 | 0 | | | | | | | Announcement under Regulation 30 (LODR)-Change in Directorate | 01/07/22 17:05 | Company Update | | | | Appointment of Dr. Kamal K Sharma (DIN: 00209430) as an Additional Independent Director of the Company w.e.f. 01st July, 2022 | | | | | | Update On Slump Sale Of Active Pharmaceutical Ingredient Business Of The Company | 01/07/22 16:46 | Company Update | | | | We hereby wish to inform that the Company has duly executed the Business Transfer agreement with Shilpa Pharma Lifesciences Limited (Formerly known as Shilpa Corporate Holdings Private Limited) the transferee Company which is complete and effective from 30 June 2022, closing of business hours. | | | | | | Compliances-Reg.24(A)-Annual Secretarial Compliance | 28/06/22 18:36 | Company Update | | | | In pursuance to the provisions of SEBI (Listing obligations & Disclosure Requirements) Regulation, 2015 Please find herewith the copy of Annual Secretarial Compliance Report for the Financial Year ended 31 March 2022.
We hereby request you to kindly take the same on record.
| | | | | | Closure of Trading Window | 28/06/22 12:51 | Insider Trading / SAST | | | | With reference to the above subject, we would like to inform you that pursuant to Code of Conduct for Regulating, Monitoring and Reporting Trading by Designated Persons and their Immediate Relatives, the Trading Window for dealing in the securities of the Company shall remain closed for all designated persons and their immediate relatives as covered under the said Code with effect from 1st July, 2022 till 48 hours after the declaration of Un-audited .... | | | | | | Announcement under Regulation 30 (LODR)-Newspaper Publication | 27/06/22 15:51 | Company Update | | | | Please find enclosed herewith the copies of newspaper advertisement published in Suddimoola (Kannada) and Business Line (English) regarding intimation of transfer of unclaimed dividends and equity shares of the Company for the Financial Year 2014-2015 to Investor Education and Protection Fund (IEPF) after the due date pursuant to the provisions of the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016. | | | | | | Disclosure Of Related Party Transactions For The Half Year Ended 31St March 2022 | 06/06/22 15:22 | Company Update | | | | Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 please find enclosed herewith the Disclosure of Related Party Transactions on a consolidated basis, for the period from 01st October 2021 to 31st March 2022 in the prescribed format (as specified by SEBI). | | | | | | Scrutinizer Report For NCLT Convened Secured Creditors Meeting - U/R 30 Of The SEBI(LODR) Regulations, 2015 | 31/05/22 17:00 | Company Update | | | | Scrutinizer's Report dated 30th May 2022 for the Secured Creditors meeting of Shilpa Medicare Limited convened by the Hon'ble National Company Law Tribunal ('NCLT'), Bengaluru Bench held on Friday the 27th day of May 2022 at 1.00 p.m. through Video Conference ('VC')/ Other Audio-Visual Means ('OAVM') at 'Shilpa House', # 12-6-214/A-1, Hyderabad road, Raichur - 584 135, Karnataka and concluded at 1.15 p.m. for the purpose of sanctioning the Scheme .... | | | | | | Scrutinizer Report For NCLT Convened Trade Creditors Meeting - U/R 30 Of The SEBI(LODR) Regulations, 2015 | 31/05/22 16:58 | Company Update | | | | Scrutinizer's Report dated 30th May 2022 for the Trade Creditors meeting of Shilpa Medicare Limited convened by the Hon'ble National Company Law Tribunal ('NCLT'), Bengaluru Bench held on Friday the 27th day of May 2022 at 11.00 a.m. through Video Conference ('VC')/ Other Audio-Visual Means ('OAVM') at 'Shilpa House', # 12-6-214/A-1, Hyderabad road, Raichur - 584 135, Karnataka for the purpose of sanctioning the Scheme of Amalgamation between INM .... | | | | | | Disclosure of Voting results of Court Convened Meeting (Regulation 44(3) of SEBI (LODR) Regulations, 2015) | 30/05/22 17:46 | AGM/EGM | | | | Shilpa Medicare Ltd has informed BSE regarding the details of Voting results of Court Convened Meeting, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here | | | | | | Scrutinizer Report For NCLT Convened Equity Shareholders Meeting - U/R 44 Of The SEBI(LODR) Regulations, 2015. | 30/05/22 17:29 | AGM/EGM | | | | Please find enclosed the Scrutinizer's Report dated 30" May 2022 for the Equity Shareholders meeting of Shilpa Medicare Limited convened by the Hon'ble National Company Law Tribunal ('NCLT'), Bengaluru Bench held on Friday the 27th day of May 2022 at 9.00 a.m. through Video Conference ('VC')/ Other Audio-Visual Means ('OAVM') at 'Shilpa House', # 12-6-214/A-1, Hyderabad road, Raichur - 584 135, Karnataka for the purpose of sanctioning the Scheme .... | | | | | | Announcement under Regulation 30 (LODR)-Newspaper Publication | 25/05/22 19:42 | Company Update | | | | Newspaper Publication of Audited Financial Results for the quarter and year ended 31 March 2022 | | | | | | Appointment of Company Secretary and Compliance Officer | 23/05/22 17:02 | Company Update | | | | Appointment of Company Secretary & Compliance Officer | | | | | | Board recommends Dividend | 23/05/22 16:49 | Corp. Action | | | | Shilpa Medicare Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 23, 2022, inter alia, has considered and approved the following:
- Recommendation of Dividend:
Payment of dividend of Rs. 1.10/- (110%) per equity share of face value of Rs. 1/- each for the financial year 2021-2022, subject to approval of members in the ensuing Annual General Meeting. | | | | | | Board Meeting Outcome for Outcome Of The Board Meeting | 23/05/22 16:46 | Result | | | | With reference to the captioned subject we hereby wish to inform you that the Board at its meeting held today i.e., on 23 May 2022 has inter alia considered and approved the following:
1. Approval of Financial Statements
2. Recommendation of Dividend
3. Update on Slump sale of Active Pharmaceutical Ingredient Business of the Company
4. Fund Raising plans in Shilpa Pharma Lifesciences Limited (A wholly owned subsidiary) by way of Initial Public offerings .... | | | | | | Outcome Of The Board Meeting (Audited Financial Results) | 23/05/22 16:35 | Result | | | | The audited financial results (Standalone and Consolidated) for the quarter and year ended 31 March 2022, pursuant to Regulation 33 (3) of Listing Regulations. The copy of the same including statement of assets and liabilities, statement of cash flows along with the Auditors'' Report with unmodified opinion and a declaration to the effect that the Auditors have given unmodified opinion on the Audited financial result (Standalone and Consolidated) .... | | | | | | Board to consider FY22 Results & Dividend on May 23, 2022 | 16/05/22 17:27 | Corp. Action | | | | Shilpa Medicare Ltd has informed BSE that the Meeting of the Board of Directors of the Company is scheduled on May 23, 2022 inter alia to transact the following business items :
1. Approval of the Audited Standalone and Consolidated Financial Results of the Company for the fourth quarter and the financial year ended March 31, 2022.
2. Recommendation of Dividend, if any for the financial Year ended March 31, 2022. | | | | | | Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015. | 16/05/22 16:47 | Board Meeting | | | | SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2022 ,inter alia, to consider and approve 1. Approval of the Audited Standalone and Consolidated Financial Results of the Company for the fourth quarter and the financial year ended 31 March 2022
2. Recommendation of Dividend, if any for the financial Year ended 31 March 2022 | | | | | | US FDA Inspection Of Shilpa Medicare Limited, Unit VII, Analytical Services Division | 02/05/22 12:05 | Company Update | | | | This is to inform you that the Company's recently started Analytical Services Division situated on first Floor of Unit 7, Nacharam, Hyderabad, Telangana was inspected by US FDA during 26 Apr 2022 to 29 Apr 2022. | | | |
|
| |
Archives |
<< Previous | Next >>
|
|
<< Back To Announcements
|